Biocon Limited — Important, 12-01-2025: Updates

The U.S. FDA has classified Biocon Biologics' facilities in Johor Bahru, Malaysia, as Voluntary Action Indicated (VAI), following a cGMP inspection conducted from September 15 to 27, 2024. This inspection covered multiple manufacturing units, including drug substance and product facilities, as well as medical device assembly and quality control labs. The classification indicates that while there were no major issues, Biocon Biologics must continue adhering to global quality and compliance standards. This development reinforces the company’s commitment to maintaining high operational standards, thus potentially mitigative of any risks pertaining to regulatory compliance in future operations. Investors should monitor the situation closely as ongoing compliance will be critical for sustained performance and market trust.